Gain Therapeutics
Preclinical stage biotech company developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx® technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $7.0m | Post IPO Equity |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 471 % | (15 %) | (61 %) | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (8336 %) | (12620 %) | (39399 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (8419 %) | (12555 %) | (40355 %) | - | - | (42804 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4342 % | 5979 % | 20879 % | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Gain Therapeutics is a biotechnology company focused on developing innovative small molecule therapeutics for disorders with high unmet medical needs. Utilizing a combination of physics-based methods and artificial intelligence, Gain Therapeutics creates next-generation allosteric small molecules that can modulate proteins to restore or disrupt their function. These molecules can inhibit, activate, stabilize, destabilize, or degrade proteins based on the specific disease pathology. The company primarily serves the healthcare and pharmaceutical sectors, targeting conditions that currently lack effective treatments. Gain Therapeutics operates in the global biotechnology market and follows a business-to-business (B2B) model, partnering with other pharmaceutical companies for clinical development and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates.
Keywords: biotechnology, small molecules, allosteric modulation, protein regulation, AI-driven drug discovery, high unmet need, healthcare, pharmaceuticals, B2B, licensing agreements.